Latest News

Expedeon Appoints Steve Howell as Non-Executive Director

February 1st, 2016

Cambridge, UK, 01 February 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the appointment of Professor Steve Howell to the Board of Directors. Steve has over 20 years of experience building and growing life science enterprises, including founding life science investment company Innova Partnerships in 2006. Prior to this he…

View

Expedeon Introduces Thunder-Link® PLUS

January 18th, 2016

New improved antibody oligonucleotide conjugation kit Cambridge, UK, 18 January 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the launch of Thunder-Link® PLUS, a new and improved version of the original Thunder-Link kit, enabling even faster and more efficient oligonucleotide conjugation. The new kit offers all of the advantages of…

View

Expedeon Installs Colloidal Gold Bulk Production Capability

November 16th, 2015

Bulk production facility enables company to support large diagnostics customers Cambridge, UK, 16 November 2015: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the installation of bulk production capability for its colloidal gold nanoparticle products. The move enables the company to support any scale of operation, including the largest players in…

View

Expedeon and Mologic Sign Supply and Licensing Agreement

July 27th, 2015

License covers use of Innova’s Lightning-Link and InnovaCoat GOLD technologies in Mologic’s kits and services Cambridge and Bedford, UK, 27 July 2015: Expedeon (Innova), a specialist provider of bioconjugation products and services, and Mologic, a specialist diagnostic development company and molecular reagent innovator, announced today the signing of a supply and licensing agreement for use…

View

Expedeon Introduces Lightning-Link Rapid Bioconjugation Kits

November 3rd, 2014

New kits enable customers to conjugate primary antibodies in 20 minutes Cambridge, UK, 3rd November 2014: Expedeon (Innova), a specialist provider of bioconjugation products and services, announced today the launch of new antibody and protein labelling kits within its Lightning-Link® Rapid range. These kits enable researchers to label primary antibodies or other proteins in just…

View

Expedeon Introduces InnovaGOLD Nanoparticles

August 28th, 2014

New ultra-high quality gold nanoparticles simplify assay development and improve the sensitivity of immunoassays Cambridge, UK, 28th August 2014: Expedeon (Innova), a specialist provider of bioconjugation products and services, announced today the commercial launch of InnovaGOLD, a new range of ultra-high quality gold nanoparticles that have demonstrated improved sensitivity, stability and reproducibility in immunoassays compared…

View

Expedeon and TGR BioSciences Announce Co-Marketing Agreement for Core Technologies

January 16th, 2014

Combining Innova’s Lightning-Link® conjugation kits with TGR’s CaptSure™ ELISA technology simplifies ELISA development and improves sensitivity Cambridge, UK and Adelaide, Australia, 16 January 2014: TGR BioSciences Pty Ltd (TGR), a life sciences company focused on the development of rapid, high sensitivity ELISA systems using their CaptSure technology, and Expedeon (Innova), a specialist provider of bioconjugation…

View

Expedeon Ltd achieves InnovaCoat® key scale-up target

November 12th, 2013

Expedeon, the inventor of high quality, easy to use bioconjugation kits, is pleased to announce it has reached yet another significant milestone of its programme funded by the UK’s innovation agency, the Technology Strategy Board, by meeting a key scale-up target for the production of its unique InnovaCoat® gold nanoparticle conjugation reagents. Traditional passive methods…

View

Expedeon Develops Site-Specific Bioconjugation Technology

August 27th, 2013

Expedeon, the inventor of the world’s easiest to use antibody labeling kits, is pleased to announce the launch of a site-specific bioconjugation technology for attaching antibodies to gold nanoparticles. Innova’s core business is ‘bioconjugation’ – the joining of two molecules to form a hybrid ‘conjugate’. Conjugates are used in diagnostic tests in hospitals and research…

View

VolitionRx to use Expedeon’ Biotin Technology in its Epigenetic Research Kits

July 21st, 2013

In-licensing deal between VolitionRx and UK-based Expedeon helps drive development of novel cancer diagnostics VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Expedeon, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Expedeon will supply its…

View

Lightning-Link® In-licensing Deal Enhances ImmunoReagents’ Product Offering to the Diagnostic Industry

April 29th, 2013

ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Expedeon (Cambridge, UK) Lightning-Link® technology for commercial purposes. Through the commercialisation deal, ImmunoReagents will utilise Innova’s technology for the manufacture of antibody conjugates, taking advantage of the very rapid Lightning Link…

View

Expedeon Develops Technology to Increase Sensitivity of Diagnostic Tests

February 19th, 2013

World healthcare models are continuously facing financial challenges when it comes to providing for an ageing population. The current models for provision are increasingly questioned with the upward trend in healthcare spending becoming a significant portion of the GDP. One solution to alleviate the ever increasing burden is earlier detection of disease using more accurate…

View